Right to Try Law Fails Patients Despite FDA Rejection of RP1 Melanoma Therapy
The FDA’s rejection of RP1, an experimental melanoma treatment, highlights the limitations of the 2018 Right to Try Act. Despite its promise to grant...
The FDA’s rejection of RP1, an experimental melanoma treatment, highlights the limitations of the 2018 Right to Try Act. Despite its promise to grant...
A new survey reveals that 57% of patient groups rated pharmaceutical companies' reputation as 'excellent' or 'good' in 2025, up from 56% in 2024. Whil...